Related Experiment Video

Updated: Sep 14, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K

Cytokine Therapy in Bladder Cancer: Mechanisms, Efficacy, and Future Prospects

Hayden J Oyler1, Layne G Bruton1, Austin J Maher2

  • 1Department of Microbiology, Immunology & Pathology, Des Moines University, West Des Moines, IA 50266, USA.

Current Issues in Molecular Biology
|July 23, 2025
PubMed

Insights

Cytokine therapy shows promise for bladder cancer by boosting immune response. Continued research is vital to overcome challenges like toxicity and improve treatments.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Bladder cancer treatment landscape requires novel therapeutic strategies.
  • Cytokine-based therapies offer a promising avenue for immune modulation in cancer.
  • Understanding cytokine roles is crucial for targeted cancer treatment.

Purpose of the Study:

  • To review the current state of cytokine therapy in bladder cancer research.
  • To explore various types of cytokines and their therapeutic applications.
  • To identify challenges and future directions for cytokine-based bladder cancer treatments.

Main Methods:

  • Literature review of pro-inflammatory cytokines, anti-inflammatory cytokines, engineered cytokines, and fusion proteins.
  • Analysis of combination therapies involving cytokines.
  • Examination of challenges such as toxicity, immune suppression, and metastasis.

Main Results:

  • Cytokine therapies aim to enhance immune responses for tumor cell elimination.
  • Engineered cytokines and fusion proteins represent advanced therapeutic approaches.
  • Combination therapies may offer synergistic effects in bladder cancer treatment.

Conclusions:

  • Cytokine therapy holds significant potential for developing effective bladder cancer treatments.
  • Overcoming challenges like toxicity and metastasis is key to clinical success.
  • Further investigation is essential for safe, minimally invasive cytokine-based therapies.
Keywords:
anti-inflammatory cytokinesbladder cancercytokine therapyengineered cytokinesfusion proteinsimmunotherapypro-inflammatory cytokines

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.6K
Mouse Bladder Wall Injection03:48

Mouse Bladder Wall Injection

Published on: July 12, 2011

24.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
346
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.2K